[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diminished-ovarian-reserve-dor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diminished-ovarian-reserve-dor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,74,103,141,162,188,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636665","multi-site-cortical-puncture-for-dor-100636665",false,"NCT07568639","Multi-Site Cortical Puncture for DOR","Clinical Efficacy and Safety of Multiple Ovarian Cortex Punctures in Improving Ovarian Reserve and Ovarian Stimulation Outcomes in Patients With Diminished Ovarian Reserve (DOR): A Multicenter, Prospective, Randomized Controlled Clinical Trial","MSCPD","Inclusion Criteria:\n\n1. Age 20-45 years;\n2. Infertile women meeting the diagnostic criteria for diminished ovarian reserve (DOR); The following two criteria must be met simultaneously: ① Anti-Müllerian hormone (AMH) ≤0.5 ng\u002Fml, ② Bilateral ovarian antral follicles (AFC) ≤5 (3-9 mm).\n3. Patients scheduled for IVF (in vitro fertilization)\u002FICSI (intracytoplasmic sperm injection) treatment;\n4. Patients who plan for whole embryo cryopreservation and intend to undergo another ovulation induction cycle within 4 natural months starting from the first cycle, with the goal of embryo retrieval and embryo banking;\n5. Bilateral follicles were observed during AFC examination;\n6. The planned ovarian stimulation protocol is one of PPOS, antagonist, or microstimulation protocols;\n7. The first ovulation induction protocol is planned to be consistent with the second ovulation induction protocol;\n8. Voluntary participation in the study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with the following reproductive and gynecological comorbidities: history of salpingectomy, ovarian cysts (e.g., chocolate cysts), ovarian tumors, or simple cysts ≥10 mm (not eligible for enrollment in the current cycle; may be enrolled after regression), history of ovarian surgery, endometriosis or adenomyosis, or acute pelvic inflammatory disease;\n2. Patients with abnormal ovarian position who are expected to experience difficulties during oocyte retrieval puncture;\n3. Patients with concomitant systemic severe diseases (history of severe chronic diseases such as heart failure, myocardial infarction, stroke, end-stage renal disease; advanced cancer or other terminal illnesses with an estimated survival period of less than 6 months; coagulation disorders; uncontrolled sepsis; autoimmune diseases; poor general condition rendering anesthesia and surgery intolerable);\n4. Patients with contraindications to hormone replacement therapy;\n5. Currently undergoing treatment with cytotoxic drugs, glucocorticoids or other immunosuppressants, radiotherapy or chemotherapy, or having previously received radiotherapy or chemotherapy;\n6. One spouse has chromosomal abnormalities;\n7. Patients with a history of uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders, where the investigator determines that clinical severity affects compliance with the clinical study;\n8. Patients who have undergone oocyte retrieval or ovarian puncture within the past year;\n9. Participating in other clinical trials.","FEMALE","20 Years","45 Years",{"count":21,"type":22},214,"ESTIMATED","INTERVENTIONAL",[25],"NA","A multicenter, prospective, randomized controlled clinical trial. The target population consists of patients undergoing IVF\u002FICSI artificial reproduction who plan to undergo ovarian stimulation and embryo retrieval (DOR) within 4 months. A stratified block randomization method was employed to assign participants in a 1:1 ratio to the intervention group and control group. The study aims to investigate whether multiple-point ovarian cortex puncture during the initial oocyte retrieval procedure improves ovarian reserve and ovarian stimulation outcomes in DOR patients compared to conventional oocyte retrieval techniques.",[28],"Diminished Ovarian Reserve (DOR)",[30,31,32],"Diminished ovarian reserve (DOR)","RCT","cortex punctures","NOT_YET_RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":22},"2026-04-30",{"date":41,"type":22},"2030-12-30",{"name":43,"class":44},"First Affiliated Hospital of Guangxi Medical University","OTHER",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100635308","phase-3-yulinzhu-for-women-with-diminished-ovarian-reserve-100635308","NCT07550998","Yulinzhu for Women With Diminished Ovarian Reserve","Yulinzhu for Women With Diminished Ovarian Reserve: a Randomized, Waiting-list Controlled, Crossover Trial","DOR","Inclusion Criteria:\n\n1. Women aged 18-40, with regular menstruation (cycle from 21 to 35 days) and reduced fertility (infertility, early miscarriage, recurrent pregnancy loss, recurrent implantation failure, etc.) ;\n2. Tests of ovarian reserve within 6 months:\n\n   1. AMH \\\u003C 1.1 ng\u002Fml or (any day in cycle, refer to laboratory standards);\n   2. AFC \\\u003C 7 follicles or (any day in cycle);\n   3. Received \\\u003C3 cycles of IVF in public sector;\n3. Subject has no history of allergy to TCM;\n4. Subjects agree to receive IVF treatment upon the completion of this research within 12 weeks if they are not pregnant spontaneously; and\n5. As diagnosed by Chinese Medicine practitioner through four diagnostic methods, suitable to receive Yulinzhu.\n\nExclusion Criteria:\n\n1. Previous history of a unilateral or bilateral oophorectomy;\n2. Recent administration of TCM for DOR within 3 months;\n3. Diagnosis of pregnancy, premature ovarian failure, residual follicles, cysts or space-occupying lesions in the ovary, pelvic inflammatory disease or polycystic ovary syndrome; and\n4. Cancer, untreated thyroid dysfunction, severe cardiovascular\u002Fcerebrovascular diseases, severe liver\u002Fkidney diseases or hematopoietic system diseases.\n5. Subjects are allowed to withdraw from the trial for one of the following reasons:\n\n(1) The patient fails to complete treatment due to safety or medical reasons; (2) The patient fails to follow treatment guidelines; (3) The patient is unwilling to continue treatment for any reason.","18 Years","40 Years",{"count":57,"type":22},60,[59],"PHASE3","This is a randomized waiting-list controlled crossover trial carried out to investigate the efficacy of traditional Chinese medicine (TCM) for DOR and its potential beneficial effects on fertility. Subjects' (1) Ovarian function (AMH, FSH), (2) Bilateral AFC as shown in pelvic ultrasound, and (3) Traditional Chinese Medicine Symptom Score (TCMSS) will be recorded. It is hypothesized that a 12-week course (5 days medication per week) of TCM herbal therapy for DOR patients will improve one or more of the above aspects when compared to the waiting-list control group.",[28],[63,64,65],"Chinese Medicine","diminished ovarian reserve","Yulinzhu","2026-04-19",{"date":68,"type":37},"2026-04-24",{"date":68,"type":22},{"date":71,"type":22},"2027-10-31",{"name":73,"class":44},"The University of Hong Kong",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":55,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100621915","phase-3-clinical-and-metabolomics-studies-on-the-improvement-of-ovarian-reserve-by-acupoint-photodynamic-therapy-and-traditional-chinese-medicine-treatment-100621915","NCT07376824","Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment","Inclusion Criteria:\n\n* Female patients aged 25 to 40 years\n\n  * Meet the diagnostic criteria for diminished ovarian reserve (requiring at least two of the following: Basal FSH 10-25 IU\u002FL; AMH \\\u003C 1.1 ng\u002FmL; AFC \\\u003C 7) ③ Meet the diagnostic criteria for kidney deficiency syndrome in traditional Chinese medicine ④ Voluntarily participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n* Organic lesions such as ovarian tumors, pituitary adenomas, endometrial tuberculosis, intrauterine adhesions or endometrial damage after abortion, as well as polycystic ovary syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, and thyroid dysfunction\n\n  * Female infertility patients who have been treated with sex hormones in the past 3 months ③ Serious or unstable physical diseases, including liver, kidney, gastrointestinal, cardiovascular, respiratory, endocrine, neurological, immune or hematological, neurological and psychiatric systems,\n\n    * History of substance (alcohol or drug) abuse or dependence within the past 3 months; heavy smokers (defined as those who smoke 20 or more cigarettes per day)\n\n      * Previous allergy to the investigational drug or photosensitivity, or individuals with contraindications to Dingkun Dan ⑥ Have participated in another clinical trial of a investigational drug within the month prior to inclusion in this study (first interview) ⑦ Other conditions that, in the judgment of the investigator, may reduce the likelihood of enrollment or complicate the enrollment process, such as frequent job changes or other circumstances prone to loss to follow-up.",true,"25 Years",{"count":83,"type":22},90,[59],"Diminished Ovarian Reserve (DOR) refers to a reduction in the number of recruitable follicles in the ovaries and\u002For a decline in oocyte quality. Current research on its etiology and treatment remains unsatisfactory. This study will be conducted as a single-center, prospective, parallel, randomized, controlled clinical trial in DOR patients. Eligible subjects will be randomly assigned to three groups: LLLT (acupoint photodynamic therapy) + placebo (Dingkun Dan Simulant), LLLT (acupoint photodynamic therapy) + Chinese medicine (Dingkun Dan), and Chinese medicine (Dingkun Dan) alone. Clinical data and serum metabolomics will be assessed at baseline and after the 3-month treatment.",[28],[64,88,89,90,91],"Integrated Traditional Chinese and Western Clinical Medicine","Randomized controlled trial","Photodynamic Therapy","metabolomics","RECRUITING","2026-01-21",{"date":95,"type":37},"2026-01-29",{"date":97,"type":37},"2024-12-20",{"date":99,"type":22},"2026-12-31",{"name":101,"class":44},"Peking Union Medical College Hospital",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":102},"100619647","phase-3-testing-herbal-pretreatment-for-ivf-success-in-women-with-low-ovarian-reserve-100619647","NCT07347340","Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve","Effectiveness Of Bushen Tongzhi Formula Pretreatment On Pregnancy Outcomes In Infertile Women With Diminished Ovarian Reserve Undergoing In Vitro Fertilization And Embryo Transfer: Study Protocol For A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (PRIME Study)","PRIME","Inclusion Criteria:\n\n* Women aged 22 to 39 years (inclusive).\n* Diagnosis of diminished ovarian reserve (DOR), defined by meeting at least two of the following three criteria: 1, Basal follicle-stimulating hormone (FSH) level between 10 and 25 IU\u002FL (measured on menstrual cycle days 2-4); 2, Anti-Müllerian hormone (AMH) level \\\u003C 1.1 ng\u002FmL; 3, Antral follicle count (AFC) \\\u003C 7 (total count of follicles 2-10 mm in diameter in both ovaries).\n* Diagnosis of infertility, defined as failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.\n* Diagnosis of Kidney Deficiency pattern according to Traditional Chinese Medicine criteria, as defined in the study protocol.\n* Scheduled to undergo a fresh in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Uterine structural abnormalities likely to impair implantation or pregnancy (e.g., untreated submucosal fibroids, severe intrauterine adhesions, uterine septum).\n* Known abnormal karyotype in either partner.\n* Uncontrolled or severe medical conditions (e.g., hypertension, diabetes, thyroid dysfunction, hepatic\u002Frenal insufficiency, symptomatic heart disease).\n* Diagnosed severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n* History of prior pelvic radiation or cytotoxic chemotherapy.\n* Active genital tract infection.\n* Diagnosed or suspected severe (ASRM stage III-IV) endometriosis with recurrent symptoms.\n* Planned use of donor oocytes or preimplantation genetic testing (PGT).\n* History of repeated IVF\u002FICSI failure (≥3 failed egg retrieval cycles or ≥3 failed transfers of high-quality embryos).\n* Known allergy to any component of the investigational herbal formula.\n* Participation in another clinical trial within the past 3 months.\n* Use of medications known to affect ovarian function (e.g., DHEA, growth hormone) within the past month.\n* Current heavy alcohol consumption or smoking.\n* Any other condition deemed by the investigator to make the participant unsuitable for the study.","22 Years","39 Years",{"count":114,"type":22},348,[59],"The goal of this clinical trial is to learn if a traditional Chinese herbal pretreatment can improve pregnancy outcomes in infertile women with diminished ovarian reserve (DOR) who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The main question it aims to answer is:\n\n• Does pretreatment with the Bushen Tongzhi Formula increase the cumulative clinical pregnancy rate from a single egg retrieval cycle compared to a placebo?\n\nResearchers will compare the group taking the herbal formula to the group taking a placebo to see if the herbal formula is more effective.\n\nParticipants will:\n\n* Take the assigned study medication (herbal formula or placebo) three times daily for 3 months before starting IVF\u002FICSI.\n* Continue taking the medication during their IVF\u002FICSI treatment cycle, for up to 6 months total.\n* Undergo standard IVF\u002FICSI procedures as planned by their doctor.\n* Have their pregnancy outcomes and health monitored through clinic visits and their medical records.",[28],[119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Traditional Chinese Medicine","Bushen Tongzhi Formula","Diminished Ovarian Reserve","Infertility","In Vitro Fertilization","Randomized Controlled Trial","Multicenter Study","Herbal Medicine","Adjuvant Therapy","Ovarian Response","Pregnancy Rate","Kidney Deficiency","Chinese Medicine Pattern","PRIME Study","2026-01-08",{"date":135,"type":37},"2026-01-16",{"date":137,"type":22},"2026-01-01",{"date":139,"type":22},"2028-06-01",{"name":101,"class":44},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":102},"100615746","phase-3-clinical-evaluation-of-integrated-chinese-western-medicine-for-infertility-with-dor-patients-in-women-achieving-natural-pregnancy-100615746","NCT07296614","Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy","Integrative Chinese and Western Medicine for Diminished Ovarian Reserve-Associated Infertility in Natural Conception Population","Inclusion Criteria:\n\n1. Female patients aged 22 to 39 years (inclusive).\n2. Meet the diagnostic criteria for diminished ovarian reserve (requiring at least two of the following: Basal FSH 10-25 IU\u002FL; AMH \\\u003C 1.1 ng\u002FmL; AFC \\\u003C 7) and infertility(defined as the failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse).\n3. Meet the diagnostic criteria for kidney deficiency syndrome in traditional Chinese medicine\n4. Voluntarily participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with premature ovarian insufficiency or premature ovarian failure (basal FSH \\>25 IU\u002FL), organic pathologies such as ovarian tumors, endometrial tuberculosis, intrauterine adhesions, or endometrial injuries, as well as those with congenital adrenal hyperplasia or Cushing's syndrome;\n2. Infertility caused by organic lesions of the fallopian tubes, uterus, cervix, etc.\n3. Infertility due to male factors (based on semen analysis reports, meeting the diagnostic criteria for oligoasthenoteratozoospermia according to the WHO 5th edition standards).\n4. DOR caused by iatrogenic factors (such as pelvic surgery, radiotherapy\u002Fchemotherapy, uterine artery embolization, etc.).\n5. Patients with severe primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, or psychiatric disorders.\n6. Individuals with known allergies to the investigational drug or its components.\n7. Use of hormonal medications (e.g., estrogen, contraceptive drugs) within one month prior to enrollment, or use of kidney-tonifying Chinese herbal medicines or proprietary Chinese medicinal products within one month prior to enrollment.\n8. Patients currently participating in or planning to participate in other clinical trials.",{"count":149,"type":22},320,[59],"This study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen (\"Xiehe DOR Bushen Tongzhi Formula\" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulation induction therapy with ovulation monitoring and timed intercourse) in improving the natural cumulative clinical pregnancy rate in infertile patients with kidney deficiency-type diminished ovarian reserve (DOR).",[28,122],[30,122,88,89],"2025-12-18",{"date":156,"type":37},"2025-12-22",{"date":158,"type":22},"2025-12-25",{"date":160,"type":22},"2028-07-30",{"name":101,"class":44},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":102},"100611911","a-randomized-controlled-study-on-the-effect-of-mrjps-on-improving-ovarian-function-and-endometrial-receptivity-100611911","NCT07246733","A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity","Inclusion Criteria:\n\n* Fertile women, aged 20 to 45 years old, with regular and normal menstrual cycles.\n\nExclusion Criteria:\n\n* ① Allergic to royal jelly or its components; ② Suffering from severe chronic diseases or endocrine system disorders; ③ Pregnant or breastfeeding; ④ Undergoing hormone replacement therapy (HRT) within the last month",{"count":169,"type":22},66,[25],"This study will assess the effects of the rose tablet candies produced by MRJPs on the subjects, evaluate the role of MRJPs in the ovarian function and endometrial receptivity of women, reveal the potential application value of MRJPs in reproductive health, and determine its safety and effectiveness.",[28,173],"Thin Endometrium",[175,176,177,178],"Ovarian reserve","Endometrial receptivity","Major Royal Jelly Proteins（MRJPs）","Reproductive health","2025-11-20",{"date":181,"type":37},"2025-11-24",{"date":183,"type":37},"2025-07-01",{"date":185,"type":22},"2028-07-31",{"name":187,"class":44},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100603874","the-clinical-trial-of-electro-thumbtack-needle-on-live-birth-rate-in-patients-with-ovarian-reserve-dysfunction-dor-100603874","NCT07142187","The Clinical Trial of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR)","The Effect of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR): a Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* The age range is 18-40 years old;\n* Meets the diagnostic criteria for DOR as follows: ① AMH\\\u003C1.1 ng\u002Fml; ② 10 U\u002FL \\\u003C FSH \\\u003C 25U\u002FL or FSH\u002FLH \\> 3.6; ③ The total number of follicles (AFC) in both basal sinuses is less than 7. If any two of the above criteria (①②③) are met, it can be diagnosed as DOR.\n* At least one side of the patient's fallopian tube is unobstructed;\n* The semen routine examination of the patient's spouse is normal;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Chromosomal or genetic abnormalities in either the female or male partner;\n* Women with blocked fallopian tubes on both sides;\n* Have a history of ovarian surgery, such as ovarian teratoma or ovarian chocolate cyst surgery;\n* The female party suffers from uncorrected endocrine disorders such as simple hyperthyroidism or hypothyroidism, hyperprolactinemia, and pancreatic islet dysfunction;\n* Hormone resistance, diabetes, adrenal diseases, etc;\n* The woman has a clearly diagnosed autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis;\n* Antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis, etc;\n* The female or male partner has a history of malignant tumors and has received treatment with radiotherapy and chemotherapy;\n* The woman has received acupuncture and moxibustion or press acupuncture treatment in recent 3 months;\n* Those who take traditional Chinese medicine decoctions or granules during treatment;\n* Men with abnormal semen examination;\n* Clear diagnosis of moderate or severe adenomyosis;\n* Clearly diagnose uterine fibroids with a diameter greater than 5cm;\n* I do not agree to sign the informed consent form for this study.",{"count":196,"type":22},368,[25],"This study will include 246 patients with ovarian reserve dysfunction (DOR), who will be randomly divided into a treatment group and a control group, with 123 patients in each group. The treatment group will receive electro-thumbtack needle treatment, while the control group will receive placebo electro-thumbtack needle treatment. Both groups will receive a treatment course of 3 menstrual cycles. This study evaluates the effect of electrocautery on the live birth rate of patients with DOR.",[28],"2025-08-24",{"date":202,"type":37},"2025-08-26",{"date":204,"type":22},"2025-10-01",{"date":206,"type":22},"2029-10-30",{"name":208,"class":44},"Huazhong University of Science and Technology",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100601990","safety-and-efficacy-of-autologous-adipose-derived-regenerative-cells-adrcs-injection-for-improving-diminished-ovarian-reserve-100601990","NCT07117682","Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve","Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE) - A Single-arm Self-controlled Study","ARISE-01","Inclusion Criteria:\n\n1. Female patients aged 20-39 years.\n2. Diagnosed with DOR, defined as AFC \\\u003C 7 and\u002For AMH ≤ 1.1 ng\u002FmL.\n3. FSH ≤ 40 U\u002FL.\n4. Have signed informed consent for the clinical trial.\n5. In good general health and able to tolerate local anesthesia, liposuction, oocyte retrieval, as well as pregnancy and childbirth.\n6. Without relative contraindications to fertility such as hereditary tumor-related diseases.\n\nExclusion Criteria:\n\n1. Presence of thyroid disorders.\n2. Body Mass Index (BMI) \\\u003C 18 kg\u002Fm².\n3. Confirmed pregnancy (positive β-hCG with ultrasound confirmation of embryo implantation).\n4. History of autoimmune diseases.\n5. Family history of ovarian tumors.\n6. Prior pelvic or systemic radiotherapy for cancer treatment.\n7. Positive serology\u002Fvirology results for human immunodeficiency virus (HIV), Hepatitis C, Hepatitis B, Syphilis, human papillomavirus (HPV), or abnormal ThinPrep cytology (TCT).\n8. DOR caused by genetic disorders.\n9. Reproductive system pathologies including polycystic ovary syndrome (PCOS), adenomyosis, uterine fibroids ≥ 5 cm, endometrial carcinoma, or uterine malformations.\n10. Contraindications to liposuction.\n11. Abnormal semen analysis of the male partner precluding natural conception or conception via assisted reproductive technology (ART).\n12. Malignancy-related conditions such as active malignancy without complete remission or chemotherapy administration within the past 6 months.",{"count":218,"type":22},25,[25],"Diminished Ovarian Reserve (DOR) poses significant challenges to fertility and hormonal health, with limited effective treatments. This prospective, self-controlled clinical study evaluates the safety and efficacy of intraovarian injection of autologous Adipose-Derived Regenerative Cells (ADRCs) to improve ovarian function in reproductive-aged women with DOR.\n\nThe ARISE trail enrolled 25 women aged \\\u003C40 years meeting clinical criteria for DOR, excluding those with severe comorbidities. Autologous adipose tissue was harvested via liposuction, and ADRCs were isolated using the Celution® system before bilateral ovarian medulla injection. Participants underwent follow-up at multiple time points up to 12 months post-procedure.\n\nPrimary outcomes included cumulative clinical pregnancy rates (natural or via ART) within 12 months and 1-, 2-, 3-, 6-month changes in ovarian reserve markers (FSH, AMH, antral follicle count) in non-pregnant patients. Secondary outcomes encompassed ovarian reserve markers at 12 months, as well as menstrual pattern recovery and ovarian volume changes at 1, 2, 3, 6, 12 months. Adverse events (AEs) will be monitored at each time point.\n\nStatistical analyses followed standard principles, including mixed models for repeated measures and appropriate tests for subgroup comparisons. Sample size was determined based on feasibility and prior effect size estimates to ensure adequate power.\n\nThis study provides novel insights into regenerative therapies for DOR, emphasizing safety and functional restoration.",[28,222,223],"Primary Ovarian Insufficiency (Poi)","Ovarian Failure, Premature",[121,225,226,227,228],"Adipose-Derived Regenerative Cells","anti-Müllerian hormone","follicle-stimulating hormone","antral follicle count","2025-08-05",{"date":231,"type":37},"2025-08-12",{"date":233,"type":22},"2025-08-25",{"date":235,"type":22},"2027-08-01",{"name":237,"class":238},"Cytori Therapeutics","INDUSTRY"]